ReviewCurrent HIV research2013
Opportunities to exploit non-neutralizing HIV-specific antibody activity.
Review in Current HIV research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Review
- Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview.Immunologic research · 2020Review
- Antibody-Dependent Cellular Phagocytosis of HIV-1-Infected Cells Is Efficiently Triggered by IgA Targeting HIV-1 Envelope Subunit gp41.Frontiers in immunology · 2020Article
- A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model.Journal of virology · 2019Article
- Structure-Based Vaccine Antigen Design.Annual review of medicine · 2019Review
- Knowns and Unknowns of Assaying Antibody-Dependent Cell-Mediated Cytotoxicity Against HIV-1.Frontiers in immunology · 2019Review
- IgA Targeting Human Immunodeficiency Virus-1 Envelope gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates with gp41-Specific IgG to Increase Cell Lysis.Frontiers in immunology · 2018Article
- Sex Differences in HIV Infection: Mystique Versus Machismo.Pathogens & immunity · 2018Article
- Mechanisms of Adaptive Immunity to Porcine Reproductive and Respiratory Syndrome Virus.Viruses · 2017Review
- Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects.Journal of immunology (Baltimore, Md. : 1950) · 2016Article
- Article
- Highly individual patterns of virus-immune IgG effector responses in humans.Medical microbiology and immunology · 2016Article
- NK Cells in HIV Disease.Current HIV/AIDS reports · 2016Review
- Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.Journal of virology · 2016Article
- Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology.Cell · 2015Article
- Article
- Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys.Science (New York, N.Y.) · 2015Article
- Prospects for engineering HIV-specific antibodies for enhanced effector function and half-life.Current opinion in HIV and AIDS · 2015Review
- Mucosal Immunogenicity of Genetically Modified Lactobacillus acidophilus Expressing an HIV-1 Epitope within the Surface Layer Protein.PloS one · 2015Article
- Modeling mucosal cell-associated HIV type 1 transmission in vitro.The Journal of infectious diseases · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Antibodies act as a nexus between innate and adaptive immunity: they provide a means to engage a spectrum of innate immune effector cells in order to clear viral particles and infected cells and prime antigen presentation. This functional landscape is remarkably complex, and depends on antibody isotype, subclass, and glycosylation; the expression levels and patterns of a suite of Fc receptors with both complementary and opposing activities; and a host of innate immune cells capable of differential responses to opsonized particles and present at different sites. In vivo, even neutralizing antibodies rely on their ability to act as molecular beacons and recruit innate immune effector cells in order to provide protection, and results from both human and macaque studies have implicated these effector functions in vaccinemediated protection. Thus, while enhancing effector function is a tractable handle for potentiating antibody-mediated protection from HIV infection, success will depend critically on leveraging understanding of the means by which antibodies with specific functional profiles could be elicited, which effector functions could provide optimal protection, and perhaps most critically, how to efficiently recruit the innate effector cells present at sites of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.